Penn Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Penn Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.81M	Buy	+10,600	New	+$1.57M	0.11%	99
2023 Q1	–	Sell	-3,271	Closed	-$391K	–	182
2022 Q4	$391K	Sell	3,271 -85	-3%	-$9.96K	0.04%	151
2022 Q3	$356K	Sell	3,356 -154	-4%	-$15.6K	0.04%	162
2022 Q2	$342K	Sell	3,510 -57	-2%	-$5.26K	0.04%	178
2022 Q1	$334K	Buy	3,567 +691	+24%	+$58.6K	0.03%	184
2021 Q4	$245K	Buy	2,876 +10	+0.3%	+$920	0.02%	201
2021 Q3	$275K	Sell	2,866 -149	-5%	-$14.1K	0.03%	192
2021 Q2	$293K	Sell	3,015 -28	-0.9%	-$2.68K	0.03%	204
2021 Q1	$296K	Sell	3,043 -11	-0.4%	-$1.15K	0.03%	199
2020 Q4	$293K	Sell	3,054 -19,401	-86%	-$1.87M	0.04%	189
2020 Q3	$2.22M	Buy	22,455 +8,062	+56%	+$933K	0.28%	138
2020 Q2	$1.8M	Buy	+14,393	New	+$1.59M	0.23%	152

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Penn Capital Management's NBIX Position: Q2 2026 in Review

Penn Capital Management opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 10,600 shares worth $1.81M. The stake represents 0.11% of the portfolio and ranks #99 among its holdings. This is a return to the name: Penn Capital Management previously reported a position in NBIX as recently as Q4 2022.

Penn Capital Management first reported a position in NBIX in Q2 2020 and has held it in 12 quarters since. The position peaked at $2.22M in Q3 2020. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Penn Capital Management held 10,600 shares of Neurocrine Biosciences worth $1.81M as of Q2 2026.
Neurocrine Biosciences was a new Penn Capital Management position in Q2 2026.
Neurocrine Biosciences made up 0.11% of Penn Capital Management's portfolio in Q2 2026, its #99 holding.
Penn Capital Management first reported a position in Neurocrine Biosciences in Q2 2020 and has held it in 12 quarters since.
Penn Capital Management's Neurocrine Biosciences position peaked at $2.22M in Q3 2020.
781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Penn Capital Management's 13F filing for Q2 2026, filed 30 Jul 2026.